SCHEMBL6184293

SCHEMBL6184293

COC(=O)c1nc(-c2cccc(Cl)c2)c(-c2ccc3nnn(-c4ccccc4)c3c2)[nH]1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NT5E P21589 1/20 0.41
MAPT P10636 3/20 0.40
KDM4E B2RXH2 1/20 0.40
TP53 P04637 2/20 0.39
TGFBR1 P36897 1/20 0.39
TGFBR2 P37173 1/20 0.39
GABRA2 P47869 1/20 0.39
GABRB2 P47870 1/20 0.39
MAPK14 Q16539 3/20 0.38
KMT2A Q03164 3/20 0.38
MEN1 O00255 2/20 0.38
MAPK13 O15264 1/20 0.37
RAF1 P04049 1/20 0.37
MAPK12 P53778 1/20 0.37
MAPK11 Q15759 1/20 0.37
PLA2G2A P14555 1/20 0.37
DHODH Q02127 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
MDM2 Q00987 1/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6188438 0.90 MAPK14 (0.45) NT5EMAPTTP53MAPK14KMT2A
SCHEMBL6186115 0.90 NT5E (0.42) NT5EMAPTTP53TGFBR1TGFBR2
SCHEMBL6186458 0.90 NT5E (0.43) NT5ETGFBR1TGFBR2MAPK14MAPK13
SCHEMBL6184681 0.88 NT5E (0.42) NT5ETGFBR1TGFBR2MAPK14MAPK13
SCHEMBL6204508 0.82 NT5E (0.41) NT5EMAPTTGFBR1TGFBR2MAPK14
SCHEMBL6185563 0.81 MAPK14 (0.43) NT5EKDM4EMAPK14KMT2AMEN1
SCHEMBL6182069 0.80 NT5E (0.41) NT5ETP53MAPK14ALDH1A1LMNA
SCHEMBL6183056 0.79 MAPK14 (0.43) NT5ETGFBR1MAPK14ALDH1A1SMN1; SMN2
SCHEMBL6184613 0.79 KCNMA1 (0.43) NT5EKDM4ETGFBR1MAPK14KMT2A
SCHEMBL6184877 0.75 IDO1 (0.60) NT5EMAPTKDM4ETGFBR1TGFBR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1247810-B1 Novel benzotriazoles anti-inflammatory compounds PFIZER PROD INC (US) 2005-09-07 EP disclosed
US-6664395-B2 Benzotriazole compoundsn are the potent inhibitors of MAP kinases, preferably p38 kinase. They are useful for treating inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion, ischemia PFIZER INC 2003-12-16 US disclosed
US-20030078432-A1 Novel benzotriazoles anti-inflammatory compounds PFIZER INC. 2003-04-24 US disclosed
EP-1247810-A1 Novel benzotriazoles anti-inflammatory compounds Pfizer Products Inc. (US) 2002-10-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078432-A1 Novel benzotriazoles anti-inflammatory compounds MAPK1, JAK1, RUNX1 NT5E 4156/4885MAPT 2726/4885KDM4E 4254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.